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Abstract
Background: The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) -like
therapy has improved survival in primary mediastinal B-cell lymphoma (PMBCL) patients. However, these results were
obtained in young low risk patients and a reevaluation in an unselected patient cohort is warranted.
Methods: In this study, we analyzed 80 PMBCL patients treated with a CHOP-based regimen with and without rituximab.
Results: In the non-rituximab cohort 10-year progression free survival (PFS) was 67% and 10-year overall survival (OS) was
72% versus a PFS of 95% and a OS of 92% in the rituximab group, PFS P = 0.001, OS P = 0.023. A subgroup PFS analysis
by international prognostic index (IPI) risk revealed that all risk groups benefit from addition of rituximab to induction
chemotherapy. In addition, OS probability was higher in the group of non-low risk patients who were treated with
rituximab compared to those patients who did not receive rituximab (P = 0.035). In multivariate analysis, only addition of
rituximab to induction chemotherapy and reaching complete remission (CR) after first line therapy had a beneficial effect
on both PFS and OS, whereas IPI, age, upfront high dose (HD) chemotherapy/autologous blood stem cell transplantation
(ABSCT) and rituximab maintenance had no impact on survival.
Conclusions: Our data demonstrate a survival benefit in unselected PMBCL patients treated with CHOP-like induction
regimen and additional rituximab independently of the IPI risk score.
Keywords: Primary mediastinal B-cell lymphoma (PMBCL), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and
prednisone (CHOP), International prognostic index (IPI)
Background
Primary mediastinal large B-cell lymphoma (PMBCL)
represents a distinct entity of mature B-cell lymphomas
in the WHO 2008 classification and comprises 6–12% of
all diffuse large B-cell lymphomas (DLBCL) and 2–4% of
all non-Hodgkin’s lymphomas [1, 2]. It is usually diag-
nosed during the third and fourth decade and is slightly
more common in women than in men [3–5].
The optimum treatment strategy in PMBCL patients
(choice of chemotherapy regimen and use of radiotherapy)
has so far not been determined by randomized clinical
trials. As shown by retrospective analyses, compared to
other forms of DLBCL, PMBCL appears to have a high
incidence of primary chemotherapy resistance (up to 30%)
[6] and relapse (over 20% after attained complete remission
(CR) [4] upon cyclophosphamide, doxorubicin, vincristine
and prednisone (CHOP) treatment without rituximab and
poor prognosis of primary refractory or progressive disease
[3, 6]. In the rituximab (R) era the management strategies
of PMBCL in clinical practice are largely supported by
uncontrolled prospective studies [7–9] and two main
treatment options are conceivable: 6 to 8 cycles of dose-
adjusted etoposide, prednisone vincristine cyclophospha-
mide, hydroxydaunorubicin (EPOCH-) R [8] or 6 cycles
R-CHOP with consolidative mediastinal radiation therapy
(Mabthera International Trial, [9]). In clinical practice the
choice of treatment is guided by the consideration of
potential long-term toxicities of radiation therapy, ease of
administration and less short-term toxicity of R-CHOP plus
radiation therapy versus the high risk of myelotoxicity
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(severe neutropenia in 50% of cycles) and hospitalization
for neutropenic fever (13% of cycles) following dose-
adjusted EPOCH-R [8].
However, the optimal management of PMBCL is not fully
established. As shown by a recent retrospective study of 63
PMBCL patients by Soumerai et al. a high primary induc-
tion failure rate (21%) with R-CHOP was observed in an
unselected patient cohort [10] while excellent outcomes
(overall response rate 90%) were demonstrated in the
Mabthera International Trial upon R-CHOP treatment [9].
These difference in therapy response can possibly be attrib-
uted to patient selection with a favorable prognosis under
study conditions (patients <60 years with age-adjusted
International Prognostic Index (IPI) score of 0–1, [9] versus
27% high-intermediate and 6% high-risk patients by age-
adjusted IPI, median age 37 years, ranging from 20 to 82,
[10]) and suggest a reevaluation of R-CHOP therapy in
PMBCL patients in unselected patient cohorts.
In the current study we therefore retrospectively ana-
lyzed the outcome (therapy response, progression free
and overall survival) of 80 PMBCL patients treated with
a CHOP-based regimen with and without rituximab.
Moreover, the significance of rituximab maintenance
therapy was evaluated with regard to progression free
and overall survival.
Methods
Study design, patient selection and data matching
All patients (N = 80) with newly diagnosed PMBCL that
were treated at our institution from March 1992 to Au-
gust 2013 were included into this retrospective analysis
(observational study). All patients had histologically
confirmed PMBCL. Clinical characteristics, IPI, [11]), first
line therapy (type of induction chemotherapy, radiation
therapy, high dose chemotherapy [HD]/autologous blood
stem cell transplantation [ABSCT]), response to therapy
were collected and retrospectively analyzed. Patients were
grouped and evaluated with regard to rituximab treatment
(yes/no) during induction chemotherapy or rituximab
maintenance therapy (yes/no). Patients that were treated
from 1992 to 2001/2002 did not receive rituximab during
induction therapy. From 2001/2002 until 2013 rituximab
was routinely administered as a part of induction therapy.
25 of 80 analyzed patients who participated in a multicen-
ter prospective randomized HD2002 trial (rituximab
maintenance versus observation in CD20+ B-cell
lymphomas) received rituximab maintenance therapy.
These patients were considered in the current study and
were compared to those who did not receive rituximab for
maintenance as a part of a subgroup analysis. The current
study was approved by the ethics committee University
Hospital Heidelberg without an informed consent of the
patients with regard to its retrospectivity. Research was
carried out in compliance with the Helsinki Declaration.
First line therapy
All patients received a CHOP-based therapy as induction
regimen: CHO(E)P (cyclophosphamide 750 mg/m2, i. v.,
day 1; doxorubincin 50 mg/m2, i. v., day 1; vincristine
1.4 mg/m2, maximum of 2 mg, i. v., day 1, [etoposide
100 mg/m2, i. v., days 1–3], prednisone 100 mg, p. o., days
1–5), and Mega-CHOEP (cyclophosphamide, doxorubin-
cin, vincristine, etoposide, prednisone as previously de-
scribed [12]). Rituximab (375 mg/m2) was administered as
part of induction therapy at day 0 of each cycle on a regu-
lar basis starting at 2001/2002. Indication for involved
field radiation therapy was bulky and extra-nodal disease.
Consolidation HD-BEAM (carmustine, cytarabine, mel-
phalan) and ABSCT were performed in 16 patients based
on investigators choice. If applicable, in some patients
(HD2002 trial) rituximab (375 mg/m2) maintenance ther-
apy was administered every 3 months for 2 years.
Response assessment
Therapy response was evaluated by clinical examination
and computed tomography scan of the involved lymph
node regions according to standardized response criteria
for non-Hodgkin lymphomas/PMBCL [13].
Statistical analysis
Statistical analysis was performed with R (R Development
Core Team, 2008). For descriptive statistics data are
presented as absolute numbers and percentage and as
median and range unless otherwise stated. For the compari-
son of categorical variables, Fisher’s Exact test in case of
2 × 2 contingency tables or its Freeman-Halton extension
in case of 2 x > 2 contingency tables were used. To identify
differences among groups in case of continuous variables, a
two sided independent t-test was performed. Progression-
free and overall survival (PFS, OS) were calculated and plot-
ted using Kaplan-Meier survival analysis. To calculate the
differences between the engraftment curves, a log-rank test
was used. Age, IPI, rituximab induction (yes/no), upfront
HD/ABSCT, remission post first line therapy (non- CR
versus CR) and rituximab maintenance (yes/no) were con-
sidered as clinically relevant parameters with regard to PFS
and OS and were included into multivariate analysis. Cox
proportional hazard model (semiparametric, estimation of
the hazard ration [HR], confidence interval [CI]), method
Breslow was used for multivariate analysis. For both multi-
variate PFS and OS analysis, the case number was 76, 12
events were observed and 4 observations deleted due to
missingness. A P-value <0.05 was considered statistically
significant. In case of multiple testing a P-value <0.05/k
(k = number of tests) was regarded as statistically signifi-
cant (alpha adjustment in accordance with the Bonferroni
correction).
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Results
Patients’ characteristics
Overall 80 patients with PMBCL were evaluated. Rituximab
was administered to 45 patients and 35 patients did not re-
ceive rituximab during induction chemotherapy. With regard
to the overall cohort the male:female ratio was 0.7. The me-
dian age at diagnosis was 37 (range 18–68) years. At initial
diagnosis B-symptoms were reported by 40 (50%) patients.
Advanced stage disease (stage II and IV) was observed in 20
(25%) patients. Low and low-intermediate risk IPI was found
in 50 (66%) and 13 (17%) patients, respectively. 12 (16%) and
1 (1%) patients had high-intermediate and high risk IPI,
respectively. No statistically significant differences in base line
variables were observed between both treatment groups.
Patients’ characteristics are shown in Table 1.
Significance of rituximab in induction therapy
First line treatment and response to therapy are summarized
in Table 2 for patients treated with and without rituximab.
In the rituximab cohort the patients received either 6 cy-
cles of R-CHOP or R-CHOEP as induction chemotherapy.
1 patient received 3 cycles R-CHOEP followed by 3 cycles
R-CHOP. Upon induction chemotherapy 6 (13%) and 39
(87%) patients reached a CR and partial remission (PR) re-
spectively and no primary induction failures were observed.
7 patients (16%, all of these patients reached PR after induc-
tion chemotherapy) underwent HD-BEAM chemotherapy
and ABSCT. In none of these patients an improvement of
remission status was observed upon HD chemotherapy and
ABSCT (PR pre and post HD chemotherapy in all
transplanted patients). 41 (91%) patients received radiation
therapy. Upon radiation therapy an improvement of
remission status from PR to CR was observed in 9 patients.
In one patient the remission status was not available after
radiation therapy and one patient developed progressive
disease (PD) during radiation therapy. An overall response
rate (ORR, CR and PR) of 98% (N = 43) was observed upon
first line therapy. After a median follow-up of 42 (range 6–
119) months relapse was reported in one patient. Projected
Table 1 Patients’ characteristics at PMBCL diagnosis
Overall cohort Rituximab treatment No Rituximab treatment P value
Patient number, N (%) 80 (100) 45 (56) 35 (44) /
Age at diagnosis, years 37 (18–64) 38 (19–64) 35 (18–58) 0.485
Gender, N (%) 0.360
Male 33 (41) 21 (47) 12 (34)
Female 47 (59) 24 (53) 23 (66)
B symptoms, N (%) 40 (50) 26 (58) 14 (40) 0.176
LDH elevated, N (%)a 58 (79) 33 (75) 25 (86) 0.841
LDH level at diagnosis, median U/l (range) 329 (145–1450) 327 (112–1277) 376 (145–1450) 0.439
Ann Arbor stage, N (%) 0.396
I 11 (14) 8 (18) 3 (8)
II 49 (61) 26 (58) 23 (66)
III 15 (19) 7 (15) 8 (23)
IV 5 (6) 4 (9) 1 (3)
Extranodal sites involved, N (%) 0.536
no 68 (85) 37 (82) 31 (89)
yes 12 (15) 8 (18) 4 (11)
ECOG, N (%) 0.344
0 58 (73) 33 (73) 25 (71)
1 20 (25) 12 (27) 8 (23)
2 2 (2) 0 (0) 2 (6)
IPIb, N (%) 0.397
Low risk 50 (66) 32 (71) 18 (58)
Low-intermediate risk 13 (17) 7 (16) 6 (19)
High-intermediate risk 12 (16) 5 (11) 7 (23)
High risk 1 (1) 1 (2) 0 (0)
aLDH was not available in 1 and 6 patients in the rituximab treatment and no rituximab treatment group, respectively. bIPI was not available in 4 patients in the
no rituximab treatment group. ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase
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10-year PFS rate was 95% (Fig. 1a). 3 (7%) deaths occurred
in the rituximab treatment group. Projected 10-year OS
rate was 92% (Fig. 1b).
In the non-rituximab cohort 13 (38%) of patients received
a median of 5 cycles of CHOP (range 1–8) or 6 cycles of
CHOEP (range 3–7), respectively. 4 patients received 1–
2 cycles of HAM post CHOP therapy. 8 (24%) of patients
were treated with a median of 4 cycles Mega-CHOEP
(range 1–5). One patient who was treated with 1 cycle
Mega-CHOEP received 4 additional cycles CHOEP. In one
patient the induction therapy regimen was not available.
Upon induction chemotherapy CR and PR were reached in
Table 2 PMBCL first line therapy
Overall cohort Rituximab treatment No Rituximab treatment
Patient number, N (%) 80 (100) 45 (56) 35 (44)
Induction chemotherapy regimens, N (%)a
6xR-CHOP 21 (27) 21 (47) /
6xR-CHOEP 23 (29) 23 (51) /
3xR-CHOP/3xR-CHOEP 1 (1) 1 (2) /
CHOP, median 5 (range 1–8) 13 (16) / 13 (38)
CHOEP, median 6 (range 3–7) 13 (16) / 13 (38)
Mega-CHOEP, median 4 (range 1–5) 8 (10) / 8 (24)
Response to induction chemotherapy, N (%)
CR 17 (21) 6 (13) 13 (37)
PR 60 (75) 39 (87) 19 (54)
PD 3 (4) 0 (0) 3 (9)
Consolidation HD and ABSCT, N (%) upon:
Mega-CHOEP 6 (8) 0 (0) 6 (17)
HD-BEAM 18 (23) 7 (16) 11 (31)
Overall 24 (30) 7 (16) 17 (49)
Radiation therapy, N (%) 70 (88) 41 (91) 29 (83)
Overall response after fist line therapy, N (%)b
CR 32 (41) 15 (34) 17 (49)
PR 43 (54) 28 (64) 15 (43)
PD 4 (5) 1 (2) 3 (9)
Rituximab maintenance therapy, N (%) 25 (31) 24 (53) 1 (3)
aThe induction chemotherapy regimen was not available in 1 patient in non-rituximab treatment group. bFirst line therapy includes induction chemotherapy, and
when appropriate in first line high dose (HD) chemotherapy and ABSCT and radiation therapy. Response after fist line therapy was not available in 1 patient in the
rituximab treatment group. ABSCT, autologous blood stem cell transplantation; BEAM, carmustine, etoposide, cytarabine, melphalan; CR, complete remission; HD,
high dose; PD, progressive disease; PR, partial remission; (R)-CHO(E)P, (rituximab), cyclophosphamide, hydroxydaunorubicin, vincristine, (etoposide), prednisone
Fig. 1 Progression-free survival (PFS, a) and overall survival (OS, b) of all patients treated either with (N = 45) or without (N = 35) rituximab.
Median PFS and OS not reached
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13 (37%) and 19 (54%) patients, respectively. Primary induc-
tion failure was observed in 3 (9%) patients. Consolidation
HD-BEAM or Mega-CHOEP and ABSCT were performed
in 17 (49%) patients. Radiation therapy was performed in 29
(83%) patients. No changes in remission status were docu-
mented upon radiation therapy. In 1 patient a CR was
reached upon surgical and radiation therapy. An ORR (CR
and PR) of 91% (N = 32) was observed upon first line ther-
apy. 1 patient received rituximab maintenance therapy
within the HD2002 trial. The median follow-up time was 50
(2–159) months in the non-rituximab group. 7 patients re-
lapsed after attaining PR after first line therapy. One patient
relapsed after reaching CR with first line therapy. Overall
PD/relapse was found in 11 (31%) patients in the non-
rituximab cohort. Projected 10-year PFS rate was 67% (Fig.
1a). 9 (26%) death occurred in the non-rituximab treatment
group. Projected 10-year OS rate were 72% (Fig. 1b).
The PFS probability was found to be significantly
higher in the rituximab treatment group compared to
the non-rituximab cohort (P = 0.001, HR = 0.123, CI95
0.041–0.374, Fig. 1a). A subgroup PFS analysis by IPI
risk (low versus low-, high-intermediate, and high) re-
vealed that both low risk and other than low risk
PMBCL patients benefit from addition of rituximab to
induction chemotherapy. However this result is limited
by a low case number in each subgroup and showed a
borderline significance: low risk subgroup P = 0.036,
HR = 7.308, CI95 1.168–45.703; other than low risk sub-
group P = 0.027, HR = 7.442, CI95 1.677–33.028, import-
antly due to multiple testing (k = 2) a P-value <0.025 is
considered as statistically significant, Fig. 2a.
In patients who received rituximab during induction
chemotherapy a significantly higher OS probability was ob-
served (P = 0.023, HR = 0.248, CI95 0.079–0.778, Fig. 1b). No
statistical significance was observed in low IPI risk subgroups
with regard to OS between those patients who received
rituximab and those who did not (P = 0.065, Fig. 2b). In
other than low IPI risk patients the OS probability was
higher when rituximab was administered during induction
therapy (P = 0.035, HR = 6.909, CI95 1.564–30.511, import-
antly due to multiple testing (k = 2) a P-value <0.025 is con-
sidered as statistically significant, Fig. 2b).
On multivariate analysis addition of rituximab to in-
duction chemotherapy and reaching CR after first line
therapy (induction chemotherapy, and when appropriate
HD chemotherapy/ABSCT and radiation) had a benefi-
cial effect on both PFS and OS. No statistically signifi-
cant impact of age or IPI score was observed (Table 3).
Significance of HD chemotherapy and ABSCT
7 (16%) and 17 (49%) patients treated with and without
rituximab received consolidation HD chemotherapy and
ABSCT. In the rituximab cohort HD chemotherapy and
ABSCT had no significant influence on PFS (P = 0.515, Fig.
3a) and OS (P = 0.403, Fig. 3b). In not rituximab treated
patients a favorable outcome was observed upon HD
chemotherapy and ABSCT with regard to PFS (P = 0.043,
HR = 0.284, CI95 0.086–0.936, P-value of statistical signifi-
cance <0.013, Fig. 3a) and OS (P = 0.174, Fig. 3b). However
these results were not statistically significant. In patients
who received HD chemotherapy and ABSCT rituximab
treatment had no significant influence on PFS (P = 0.251,
Fig. 3 a) and OS (P = 0.251, Fig. 3b). In contrast, in not
transplanted patients rituximab during induction therapy
significantly prolonged PFS (P < 0.001, HR = 11.165, CI95
0.2.735–45.568, P-value of statistical significance <0.013,
Fig. 3a) and OS (P = 0.012, HR = 4.906, CI95 1.162–
20.712, P-value of statistical significance <0.013, Fig. 3b).
First line HD chemotherapy and ABSCT had no statisti-
cally significant impact on PFS or OS on mulitivariate
analysis (Table 3).
Fig. 2 Progression-free survival (PFS, a) and overall survival (OS, b) of low and other than low (low-, high-intermediate, and high) risk patients by
IPI treated either with (N = 32 and N = 13) or without (N = 18 and N = 13) rituximab. IPI was not available in 4 patients in the no rituximab
treatment group. These patients were excluded from the survival analyses. Median PFS and OS not reached. Due to multiple testing (k = 2)
a P-value <0.025 is considered as statistically significant
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Significance of rituximab maintenance therapy
24 (53%) patients who had received a rituximab-
containing induction therapy (overall N = 45) received
rituximab maintenance therapy as a part of the multi-
center prospective randomized HD2002 trial. Rituximab
maintenance therapy (375 mg/m2) was administered for
2 years every 3 months. A PFS and OS evaluation and
comparison to initially rituximab treated patients with-
out rituximab maintenance therapy (N = 21, 47%) was
performed for this patient cohort (Fig. 4). No statistically
significant differences with regard to PFS (P = 0.167)
and OS (P = 0.585) were observed between patients who
received rituximab maintenance and those who did not.
Rituximab maintenance therapy had no statistically sig-
nificant impact on PFS or OS on mulitivariate analysis
(Table 3).
We present a retrospective analysis of 80 patients with
PMBCL treated with CHOP-like induction chemother-
apy with or without rituximab. Our aim was to compare
the therapeutic outcome between both treatments
groups in a “real-life” population not selected for clinical
trials. The limitations of this analysis can be attributed
to its retrospectivety and the sequential evaluation of the
patient cohorts with regard to the treatment periods
without (1992 to 2001/2002) and with (2001/2002 to
2013) rituximab (possible influence of diagnostic and
therapeutic innovations). However, the patient cohort
was homogeneous with respect to clinical parameters at
initial diagnosis (age, gender distribution, Ann Arbor
stage, ECOG, IPI) among both treatment groups. The
clinical variables corresponded well to the clinical
PMBCL features described in the literature. In particular,
PMBCL usually occurs during the third decade (rage of
median age 27–42 years) and is more common in
women than in men (46–78% of cases) [3, 5, 14–16]. In
our patient cohort the median age was 37 years and 59%
of patients were female. 50% of patients reported B-
symptoms, which is slightly more compared to the pa-
tient cohorts described in the literature (24–48%) [6, 14,
17, 18]. Lactate dehydrogenase (LDH) elevation was
found in 58% of patients, which is within the range re-
ported by other authors (52–98% of cases) [6, 14, 19,
20]. About a quarter of patients have an advanced stage
III or IV disease [4, 6, 15, 20]. In our patient cohort 19%
and 6% of patients presented with stage III and IV
PMBCL, respectively. Initial extranodal presentation is
found in 10% to 69% of cases [14, 15] and was observed
in 12% of cases in our study.
Table 3 Multivariate Cox proportional hazard analysis
PFS OS
HR (CI95) P HR (CI95) P
Age 1.057 (0.984–1.135) 0.130 1.049 (0.981–1.121) 0.161
IPI 1.433 (0.365–5.620) 0.606 2.256 (0.580–8.767) 0.240
Rituximab induction 0.065 (0.011–0.367) 0.002 0.192 (0.041–0.890) 0.035
Upfront HD/ABSCT 0.318 (0.065–1.562) 0.158 0.498 (0.095–2.617) 0.410
Remission post first line therapy (non-CR versus CR) 0.106 (0.021–0.532) 0.006 0.156 (0.032–0.748) 0.020
Rituximab maintenance 0.444 (0.046–4.264) 0.482 0.360 (0.039–3.356) 0.370
n = 76; ABSCT autologous blood stem cell transplantation, CI confidence interval, CR complete remission, HD high dose, HR Hazard ratio, IPI International
Prognostic Index, OS overall survival, PFS progression free survival
Fig. 3 Progression-free survival (PFS, a) and overall survival (OS, b) of patients treated with and without consolidation high dose chemotherapy
and ABSCT in dependency of rituximab treatment (with rituximab N = 7 and N = 38; without rituximab N = 17 and N = 18). Due to multiple
testing (k = 4) a P-value <0.013 is considered as statistically significant
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Upon CHOP-like induction chemotherapy without ri-
tuximab an ORR (CR 37%, PR 54%) of 91% was observed.
9% of patients showed primary induction failure and 23%
of patients relapsed. These response rates correspond to
the results obtained in retrospective multicenter analyses
upon CHOP-like treatment without rituximab (CR 23%,
49%, and 51%; PR 41%, 32%, and 7%) [3, 4, 6]. However,
the primary resistance to treatment observed in our pa-
tient cohort (9%) was lower compared to these multicen-
ter studies (35%, 19%, and 42%) [3, 4, 6]. Lazzarino et al.
reported an actuarial 3-year survival rate of 52% for a
series of 99 PMBCL patients assessable for a CHOP-like
induction regimen after a median follow-up of 50 months
[6]. After a median follow-up from diagnosis of 52 months
Zinzani et al. calculated projected 10-year PFS and OS
rates for CHOP-like regimens of 35% and 44% respectively
[4]. We observed higher 10-year PFS and OS rates (67%
and 72%) in our cohort treated without rituximab.
As demonstrated by Rieger et al., rituximab significantly
improved the outcome of PMBCL patients. Rituximab
added to 6 cycles of CHOP-like chemotherapy increased
the rates of complete remission (from 54% to 80% with
ORR of 90%), virtually eliminated PD (2.5% versus 24%),
and improved the 3-year event-free-survival (EFS, 78%
versus 52%) compared to CHOP-like treatment only
(Mabthera International Trial, [9]). Moreover, Dunleavy et
al. reported excellent outcome results (event-free survival
rate of 93% and OS rate of 97% during a median of 5 years
of follow-up) upon rituximab and dose-adjusted EPOCH
treatment without radiotherapy in previously untreated
PMBCL patients [8]. However, these results were obtained
on a preselected patient cohorts with favorable prognosis
(patients <60 years [8, 9], age-adjusted IPI score of 0–1,
extranodal involvement and stage III/IV PMBCL in 3% of
patients [9]. On the contrary, a recent retrospective study
of 63 PMBCL patients by Soumerai et al. demonstrated an
unacceptably high rate of primary refractory disease on R-
CHOP (21%), particularly among patients with high risk
features (age > 60 years, 27% high-intermediate and 6%
high-risk patients by age-adjusted IPI, advanced stage dis-
ease in 21% and mediastinal bulk in 71% of patients) [10].
The rituximab treated patient cohort evaluated in the
present study closely corresponds to the patient group an-
alyzed by Soumerai et al. (real-life situation, inclusion of
patients over 60 years, advanced stage disease in 24% and
not low risk IPI in 29% of cases). However, we could not
confirm the poor therapy response retrospectively
assessed by Soumerai et al. In this analysis, no patient
treated with CHOP-like regimen and additional rituximab
experienced primary resistance to induction therapy and
CR and PR rates of 13% and 87% were reached. Although
the CR rate was lower in patients who were treated with
R-CHOP compared to CHOP therapy only (13% versus
37%), a favorable outcome with regard to PFS and OS was
observed in patients that received rituximab (P = 0.001,
and P = 0.023, respectively). In particular, in not HD
chemotherapy/ABSCT setting rituximab during induction
therapy significantly prolonged PFS and OS. Interestingly,
consolidation with HD chemotherapy/ABSCT had no sig-
nificant influence on PFS and OS when rituximab was ad-
ministered during induction therapy. PMBCL patients
treated with rituximab also had a beneficial PFS outcome
when the cohort was stratified by IPI (low-, high-
intermediate, and high). In higher, but not in low risk pa-
tients an advantageous OS outcome was observed upon
rituximab treatment indicating the significance of rituxi-
mab addition to CHOP-like induction therapy in poor
prognostic PMBCL groups. Overall, the addition of rituxi-
mab to induction chemotherapy and reaching CR after
first line therapy had a beneficial effect on both PFS and
OS on multivariate analysis.
Recently, rituximab maintenance therapy (375 mg/m2
every 3 months for 2 years) was shown to improve survival
in male patients with DLBCL [21]. To the best of our know-
ledge, rituximab maintenance therapy has not been evalu-
ated in PMBCL patients so far. In our analysis rituximab
Fig. 4 Progression-free survival (PFS, a) and overall survival (OS, b) of all patients that received rituximab during induction chemotherapy (N = 45)
treated either with (N = 24) or without (N = 21) rituximab maintenance therapy. Median PFS and OS not reached
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maintenance therapy did not seem to influence PFS and OS
(P = 0.167, and P = 0.585, respectively). However, due to a
low case number (N = 24) further evaluation is warranted in
larger patient cohorts and prospective randomized trials.
Conclusion
In conclusion, our data demonstrate an advantageous out-
come (PFS and OS) in unselected PMBCL patients treated
with CHOP-like induction regimen and additional rituximab
over CHOP-like treatment only. Particularly in PMBCL
patients with poor prognosis and those treated without
consolidation HD chemotherapy and ABSCT rituximab
containing induction therapy seems to provide a beneficial
survival outcome.
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